News and History

Search (e.g. by company, location, key word)
Categories
Location
1-20 of 10,922 results

  • Gilead to Acquire Tubulis for $5 Billion to Further Strengthen Oncology Pipeline

    On Apr. 7, 2026, Gilead Sciences announced it has entered into a definitive agreement to acquire Tubulis, a

    Read More: Gilead to Acquire Tubulis for $5 Billion to Further Strengthen Oncology Pipeline

  • Life Science Industry’s Rapid Growth in Washington State Challenged by NIH Budget Cuts

    On Apr. 7, 2026, LifeScienceHistory.com, formerly WashingtonLifeScience.com, announces release of a report highlighting the challenges of Washington State’s

    Read More: Life Science Industry’s Rapid Growth in Washington State Challenged by NIH Budget Cuts

  • Zhang Kai, Yale scientist leaves for China university

    On Apr. 2, 2026, Zhang Kai, a rising cryo-electron microscopy researcher, has resigned from his tenure-track position at

    Read More: Zhang Kai, Yale scientist leaves for China university

  • FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

    On Apr. 1, 2026, Eli Lilly announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for

    Read More: FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

  • China Tops U.S. in R&D Spending

    On Mar. 31, 2026, the Organisation for Economic Co-operation and Development (OECD), reports that China has officially crept

    Read More: China Tops U.S. in R&D Spending

  • Biogen to Acquire Apellis for $5.6 billion, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease

    On Mar. 31, 2026, Biogen and Apellis Pharmaceuticals announced the companies have entered into a definitive agreement under

    Read More: Biogen to Acquire Apellis for $5.6 billion, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease

  • Lilly to acquire Centessa Pharma to advance treatments for sleep-wake disorders in deal worth up to $7.8 Billion

    On Mar. 31, 2026, Eli Lilly and Centessa Pharmaceuticals, a clinical-stage company developing a new class of medicines

    Read More: Lilly to acquire Centessa Pharma to advance treatments for sleep-wake disorders in deal worth up to $7.8 Billion

  • FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

    On Mar. 30, 2026, Biogen announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of

    Read More: FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

  • China biotech deals hit record as innovative drugs draw interest of multinationals

    On Mar. 29, 2026, The South China Morning Post reported the cross-border outlicensing activities of Chinese biotech firms

    Read More: China biotech deals hit record as innovative drugs draw interest of multinationals

  • Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly

    On Mar. 29, 2026, generative-AI drug developer Insilico Medicine announced that it has ​agreed to a global licensing

    Read More: Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly

  • NIH restrictions on foreign research partnerships significantly impacted 1 in 4 U.S. scientists

    On Mar. 27, 2026, a STAT survey conducted of nearly 1,000 National Institutes of Health (NIH) -supported scientists,

    Read More: NIH restrictions on foreign research partnerships significantly impacted 1 in 4 U.S. scientists

  • Novartis to acquire Excellergy for $2 Billion, building on allergy leadership with next-generation anti-IgE innovation

    On Mar. 27, 2026, Novartis announced an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE

    Read More: Novartis to acquire Excellergy for $2 Billion, building on allergy leadership with next-generation anti-IgE innovation

  • Implantable ‘Living Pharmacy’ Produces Multiple Drugs Inside the Body

    On Mar. 27, 2026, A multi-institutional team of scientists, co-led by Northwestern University, has taken a crucial step

    Read More: Implantable ‘Living Pharmacy’ Produces Multiple Drugs Inside the Body

  • US measles cases top 1,500 as Texas outbreak grows

    On Mar. 27, 2026, measles cases in the United States have climbed to 1,575, with 88 new infections,

    Read More: US measles cases top 1,500 as Texas outbreak grows

  • Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

    On Mar. 27, 2026, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration(FDA) has granted accelerated approval

    Read More: Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

  • PTAB sides with Broad Institute over University of California on patent priority for use of CRISPR in eukaryotic cells

    On Mar. 26, 2026, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (USPTO and PTAB,

    Read More: PTAB sides with Broad Institute over University of California on patent priority for use of CRISPR in eukaryotic cells

  • Largest Animal Health Emergency in U.S. History Continues as HPAI Devastates Indiana

    On Mar. 26, 2026, Indiana’s poultry industry continues to face significant challenges as outbreaks of highly pathogenic avian

    Read More: Largest Animal Health Emergency in U.S. History Continues as HPAI Devastates Indiana

  • Merck to Acquire Terns Pharmaceuticals for $5.7 Billion, Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia

    On Mar. 25, 2026, Merck, and Terns Pharmaceuticals, a clinical-stage oncology company, announced that the companies have entered

    Read More: Merck to Acquire Terns Pharmaceuticals for $5.7 Billion, Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia

  • ‘Dead End’: Radical 20-Year Study Reveals Genetic Cloning Hits a Limit

    On Mar. 25, 2026, researchers, led by scientists at the University of Yamanashi in Japan, cloned a single

    Read More: ‘Dead End’: Radical 20-Year Study Reveals Genetic Cloning Hits a Limit

  • WHO Data Show Pertussis (Whooping Cough) Rising in Western Pacific and Europe

    On Mar. 25, 2026, according to the latest data published by the World Health Organization (WHO), globally, 941,582

    Read More: WHO Data Show Pertussis (Whooping Cough) Rising in Western Pacific and Europe